Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer

Figure 2

Relationship between miRNA-126 and response. (A) Distribution of miRNA-126 expression levels according to response or non-response to first line XELOX in patients with mCRC, black bars represent the medians, n = 83. The difference between the medians in the two groups was significant, p = 0.000005. (B) Illustration of the same distribution divided into the four response groups (PD; progressive disease, SD; stable disease, PR; partial response and CR; complete response). A significant difference between the median miRNA-126 expression levels in the patients achieving SD compared to PR was observed, p = 0.001. The miRNA-126 expression levels from five patients (outliers, levels ranging from 16775-40284) are not shown in the figures for graphical reasons only, but were included in the statistics. Two of these patients achieved PR and the remaining three CR.

Back to article page